Prothena Hit With Stock-Drop Suit After Failed Clinical Trials
A potential class of Prothena Corp. investors on Thursday accused the clinical-trial stage biotech company in California federal court of misleading them about the success of an AL amyloidosis treatment and...To view the full article, register now.
Already a subscriber? Click here to view full article